Literature DB >> 4070935

Detection of ovarian cancer marker CA 125 in human seminal plasma.

H Halila.   

Abstract

Ovarian cancer marker CA 125-like immunoreactivity was detected in human seminal plasma. The levels were 17-720 U/ml in specimens from normospermic men (n = 35), 22-1150 U/ml in samples from 46 men with either oligo-, astheno-, terato- or necrospermia, and 36-1096 U/ml in 7 vasectomized men. No significant differences were found in the CA 125 levels between the groups studied. Low CA 125 levels (less than 35 U/ml) were detected in male sera. Serial dilutions of seminal plasma and ovarian cancer serum gave parallel dose-response curves. No correlation was observed between the age of men, sperm count, volume of seminal plasma or percent of motile spermatozooa and CA 125 levels in seminal plasma. CA 125 in seminal plasma does not seem to be of testicular origin, as the levels in vasectomized and non-vasectomized men were similar. In gel filtration, CA 125 immunoreactivity in seminal plasma and ovarian cancer serum eluted in the same volume corresponding to a molecular weight of about 130 kD.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4070935

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers.

Authors:  M Venegas; L Liu; L Lovell; L E Davis; B Anderson; T Wilbanks; M Hass; G Manderino; H Rittenhouse
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

2.  Immunoreactive determinants of CA 125 in women with endometriosis.

Authors:  O A Mojiminiyi; M E Bramwell; S H Kennedy; B J Shepstone; S M Humm; D H Barlow
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

Review 3.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.